RENEWABLE ENERGY SYSTEMS LIMITED
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., General Contractors—Nonresidential Buildings, Other than Industrial Buildings and Warehouses, Engineering Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about RENEWABLE ENERGY SYSTEMS LIMITED
Live alerts from global media, monitored by Business Radar
2024-05-20 (nature.com)
Preclinical models of bladder cancer: BBN and beyond
Preclinical modelling is a crucial component of advancing the understanding of cancer biology and therapeutic development. Several models exist for understanding the pathobiology of bladder cancer and evaluating therapeutics. N-butyl-N-( 4-hydroxybutyl) -nitrosamine( BBN) -induced bladder cancer is
Read more
2024-05-20 (nature.com)
Preclinical models of bladder cancer: BBN and beyond
Preclinical modelling is a crucial component of advancing the understanding of cancer biology and therapeutic development. Several models exist for understanding the pathobiology of bladder cancer and evaluating therapeutics. N-butyl-N-( 4-hydroxybutyl) -nitrosamine( BBN) -induced bladder cancer is
Read more
2024-04-12 (nature.com)
CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy | Cancer Gene Therapy
Cancer Gene Therapy - CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy
Read more
2023-10-31 (nature.com)
Metabolic pathway analysis using stable isotopes in patients with cancer | Reviews Cancer
Metabolic reprogramming is central to malignant transformation and cancer cell growth. How tumours use nutrients and the relative rates of reprogrammed pathways are areas of intense investigation. Tumour metabolism is determined by a complex and incompletely defined combination of factors intrinsic and extrinsic to cancer cells. This complexity increases the value of assessing cancer metabolism in disease-relevant microenvironments, including in patients with cancer. Stable-isotope tracing is an informative, versatile method for probing tumour metabolism in vivo. It has been used extensively in preclinical models of cancer and, with increasing frequency, in patients with cancer. In this Review, we describe approaches for using in vivo isotope tracing to define fuel preferences and pathway engagement in tumours, along with some of the principles that have emerged from this work.
Read more
2022-11-21 (nature.com)
A20 interacts with mTORC2 to inhibit the mTORC2/Akt/Rac1 signaling axis in hepatocellular carcinoma cells | Cancer Gene Therapy
Cancer Gene Therapy - A20 interacts with mTORC2 to inhibit the mTORC2/Akt/Rac1 signaling axis in hepatocellular carcinoma cells
Read more
2020-06-22 (nature.com)
SDCBP/MDA-9/syntenin phosphorylation by AURKA promotes esophageal squamous cell carcinoma progression through the EGFR-PI3K-Akt signaling pathway | Oncogene
Oncogene - SDCBP/MDA-9/syntenin phosphorylation by AURKA promotes esophageal squamous cell carcinoma progression through the EGFR-PI3K-Akt signaling pathway
Read more
2020-02-24 (nature.com)
PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma | Leukemia
Leukemia - PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma
Read more
2017-10-23 (nature.com)
Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors | Oncogene
Oncogene - Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors
Read more
2014-07-29 (nature.com)
Pax-8–PPAR-γ fusion protein in thyroid carcinoma
Approximately one-third of follicular thyroid carcinomas containPAX8–PPARG gene fusions, which result in the production of an oncogenic Pax 8–PPAR-γ fusion protein (PPFP). Here, Raman and Koenig describe the structure and function of PAX8 and PPARGand their protein products. They discuss possible
Read more
2014-07-21 (nature.com)
PAX genes in childhood oncogenesis: developmental biology gone awry?
Childhood solid tumors often arise from embryonal-like cells, which are distinct from the epithelial cancers observed in adults, and etiologically can be considered as ‘developmental patterning gone awry’. Paired-box( PAX) genes encode a family of evolutionarily conserved transcription factors that
Read more
2012-05-06 (nature.com)
Monoclonal TCR-redirected tumor cell killing | Medicine
T cell receptor (TCR)-based immunotherapeutic approaches have so far had limited success because of a lack of specific immune recognition and activation by the TCR. Here Nathaniel Liddy and his colleagues describe the generation, optimization and characterization of a new set of reagents—immune-mobilizing monoclonal TCRs against cancer (or ImmTACs)—designed to overcome some of these limitations. The ImmTACs were used to redirect and activate T cells to lyse tumor cells both in vitro and in vivo, even those expressing very low epitope numbers on the cell surface. T cell immunity can potentially eradicate malignant cells and lead to clinical remission in a minority of patients with cancer. In the majority of these individuals, however, there is a failure of the specific T cell receptor (TCR)–mediated immune recognition and activation process. Here we describe the engineering and characterization of new reagents termed immune-mobilizing monoclonal TCRs against cancer (ImmTACs).
Read more
2011-08-22 (nature.com)
Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma | Oncogene
Oncogene - Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma
Read more